Skip to content

The Feasibility of Drug Delivery to Infants During Breastfeeding

The Feasibility of Drug Delivery to Infants During Breastfeeding (FEDD)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03799367
Acronym
FEDD
Enrollment
26
Registered
2019-01-10
Start date
2018-07-09
Completion date
2018-12-31
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Feeding, Infant, Newborn, Medication Systems, Milk, Human

Brief summary

Parents commonly find giving medicines to babies, using oral syringes or spoons, difficult and emotionally stressful. In developing countries, additional stress arises due to hygiene difficulties and the lack of clean water. To overcome these challenges and encourage breastfeeding, we have developed the concept of a Therapeutic Nipple Shield, a delivery system that makes it possible to give medicine and nutrients to babies during breastfeeding. It consists of a silicone nipple shield that allows the release of medicine/nutrients into human milk during the feed. Presentations of a prototype to parents and staff at the Rosie Hospital was very positive, and encouraged this clinical study. This study aims to give a vitamin B12 supplement to babies during breastfeeding. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.

Interventions

DEVICEDrug delivery during breastfeeding

This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.

Sponsors

University of Cambridge
CollaboratorOTHER
Cambridge University Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Days to 12 Months
Healthy volunteers
No

Inclusion criteria

No known allergy or hypersensitivity against any ingredient used in the study Infant aged up to 12 months Confident breastfeeder (exclusively or non-exclusively)

Exclusion criteria

The participant may not enter the study if ANY of the following apply: * Not confident at breastfeeding * Infant not feeding properly * Allergy or hypersensitivity against any ingredient of the commercially available Methylcobalamin Vitamin B12 Tablets (Just Vitamins Ltd, UK) used in the study (infant or mother) * Medical conditions that could negatively influence swallowing, and thus breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Detection of the change in vitamin B12 concentration in the infants' blood 6-8 hours following vitamin B12 delivery from a nipple shield device during breastfeedingBlood sampling base line and 6-8 hours post feedTwo infant blood samples will be taken - one base line and one post intervention

Secondary

MeasureTime frameDescription
Qualitative assessment of impact on maternal expectation, experience and acceptabilityInterviews will be conducted prior to and post interventional feed and will last about 30-50 min.Semi-structured interviews will be conducted before and after vitamin B12 delivery during breastfeeding

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026